PCT After a Steroid Cycle: Why You Need It, When to Start, and What Happens If You Skip It

Post-cycle therapy is not optional. Every anabolic steroid cycle suppresses your natural testosterone production, and without PCT, recovery can take months, during which you lose muscle, gain fat, and experience the full spectrum of hypogonadal symptoms: no libido, no energy, no motivation, and a mood that makes the post-cycle period genuinely miserable. This guide from Hemi Pharma UK explains the endocrine mechanism behind PCT, how each PCT drug works at the receptor level, when to start based on your specific compounds, and what the clinical recovery data actually shows.

Why does your body need PCT after a steroid cycle?

To understand why PCT is necessary, you need to understand the feedback loop it is designed to restart. Under normal conditions, the hypothalamus secretes gonadotropin-releasing hormone (GnRH) in a pulsatile pattern. GnRH stimulates the anterior pituitary to release luteinising hormone (LH) and follicle-stimulating hormone (FSH). LH acts on the Leydig cells in the testes to produce testosterone. FSH acts on the Sertoli cells to support spermatogenesis. The testosterone produced by the Leydig cells then feeds back to the hypothalamus and pituitary, reducing GnRH, LH and FSH secretion. This is the hypothalamic-pituitary-testicular axis (HPTA), and it maintains testosterone within a physiological range.

When you introduce exogenous androgens at supraphysiological doses, the hypothalamus detects the elevated androgen (and oestrogen, from aromatisation) levels and dramatically reduces GnRH output. The pituitary follows suit, dropping LH and FSH to near zero. The Leydig cells, receiving no LH stimulation, stop producing testosterone. The Sertoli cells, receiving no FSH, stop supporting sperm production. The testes, unused, physically atrophy.

When you stop the exogenous androgens, the supraphysiological levels begin to fall. But the hypothalamus and pituitary do not immediately resume normal GnRH and LH/FSH secretion. After weeks or months of suppression, the entire axis is effectively dormant. Without intervention, recovery follows a slow, passive timeline: the exogenous compound clears, the hypothalamus gradually detects the falling androgen levels, GnRH secretion tentatively resumes, LH and FSH slowly rise, and the atrophied Leydig cells slowly begin producing testosterone again. This passive recovery can take 3 to 12 months, during which testosterone levels remain at or near castrate levels.

PCT drugs accelerate this recovery by bypassing the dormant hypothalamus and directly stimulating the pituitary to release LH and FSH before the natural feedback loop has fully reawakened.

How do SERMs work for PCT at the receptor level?

Selective oestrogen receptor modulators (SERMs) are the foundation of every PCT protocol. The two SERMs used in steroid PCT are Tamoxifen (Nolvadex) and Clomiphene (Clomid). Both work through the same fundamental mechanism, but their pharmacology differs in ways that matter for PCT selection.

Under normal physiology, oestradiol (produced by aromatisation of testosterone) provides negative feedback to the hypothalamus and pituitary. Oestradiol binds to oestrogen receptors (ERs) in these tissues and suppresses GnRH and gonadotropin release. SERMs work by binding to these same oestrogen receptors but acting as antagonists: they occupy the receptor without activating it, blocking oestradiol from binding and exerting its suppressive effect. With the oestrogen-mediated negative feedback removed, the pituitary interprets the situation as “low oestrogen” and increases LH and FSH output, even though systemic oestrogen levels may be normal or elevated.

The potency of this effect is substantial. A 2026 review in Andrology documented that Clomiphene at 50mg daily for 30 days in healthy men produced increases of 146% in total testosterone, 177% in LH, and 170% in FSH, demonstrating powerful activation of the HPG axis. A 2025 systematic review and meta-analysis of randomised controlled trials confirmed that SERM therapy significantly improved total testosterone (mean difference 273.76 ng/dL over placebo), LH (mean difference 4.66 IU/L), and FSH, and was associated with significantly enhanced LH and FSH levels compared to testosterone gel, indicating genuine endogenous axis restoration rather than simple hormone replacement.

How does Tamoxifen differ from Clomiphene for PCT?

Tamoxifen (Nolvadex) is a non-steroidal SERM that acts as an oestrogen receptor antagonist in the hypothalamus, pituitary, and breast tissue, while acting as a partial agonist in bone and uterine tissue. For PCT purposes, its antagonism at the pituitary is the relevant action: it blocks oestradiol from suppressing LH and FSH release, allowing gonadotropin levels to rise.

Clomiphene (Clomid) is also a non-steroidal SERM, but it is a mixture of two geometric isomers: enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). Enclomiphene is the active SERM that blocks oestrogen receptors at the pituitary and stimulates LH and FSH release. Zuclomiphene, however, is a weak oestrogen agonist with a much longer half-life (approximately 30 days, compared to approximately 10 hours for enclomiphene). This means zuclomiphene accumulates during a course of Clomid and can produce mild oestrogenic effects, which is thought to explain why Clomid causes a higher incidence of emotional side effects (mood swings, irritability, emotional lability) and visual disturbances (blurred vision, visual floaters) than Tamoxifen.

In practical terms, Tamoxifen is generally better tolerated and is the preferred SERM for PCT by most experienced users. Its side effect profile is milder, its oestrogen receptor antagonism in the pituitary is robust, and it provides the additional benefit of blocking oestrogen at the breast tissue, offering continued gynaecomastia protection during the vulnerable post-cycle period when oestrogen levels can fluctuate unpredictably.

Some PCT protocols use both Tamoxifen and Clomiphene together, based on the rationale that combining two SERMs with slightly different receptor binding profiles produces a stronger gonadotropin response than either alone. This approach was popularised by Dr. Michael Scally as the “Power PCT” protocol (which also includes HCG). There are no randomised controlled trials comparing dual-SERM PCT to single-SERM PCT in steroid users, so the evidence for the combined approach is empirical rather than clinical.

What role does HCG play in PCT?

Human chorionic gonadotropin (HCG) is not a SERM. It is a glycoprotein hormone that mimics the action of LH by binding to the LH receptor on Leydig cells, directly stimulating testosterone production. Its role in PCT strategy is fundamentally different from SERMs: while SERMs work upstream (at the pituitary, stimulating LH release), HCG works downstream (at the testes, bypassing the pituitary entirely).

The most current thinking in harm reduction circles favours using HCG during the cycle rather than during PCT. The rationale is preventive: on-cycle HCG (250 to 500 IU twice weekly throughout the cycle) maintains Leydig cell function and intratesticular testosterone while the HPTA is suppressed, preventing the testicular atrophy that makes post-cycle recovery slower and more difficult. Leydig cells that have been maintained with HCG throughout the cycle respond more quickly to natural LH stimulation once it returns during PCT.

Using HCG during PCT itself (the older approach) carries a risk: high-dose HCG can desensitise the LH receptor through receptor downregulation, potentially impairing the very recovery it is meant to support. If HCG is used post-cycle, it should be limited to the clearance window (the 2 to 3 weeks between the last injection of a long-estered steroid and the start of SERM therapy), at moderate doses (1000 to 1500 IU every other day for 1 to 2 weeks), and discontinued before the SERM begins.

When should you start PCT after your last injection?

PCT timing is entirely determined by the ester attached to your last injectable compound. The SERM should not begin until the exogenous androgen has cleared to a level low enough that it is no longer providing meaningful HPTA suppression. Starting the SERM while significant exogenous androgen remains in circulation is counterproductive: the androgen-mediated negative feedback overpowers the SERM’s stimulatory effect at the pituitary.

For Testosterone Enanthate and Cypionate (half-life 4.5 to 5 days): begin SERM therapy 14 days after the last injection. This allows approximately 3 half-lives of clearance, reducing blood levels to roughly 12% of peak.

For Testosterone Propionate (half-life 0.8 days): begin SERM therapy 3 days after the last injection.

For Sustanon 250 (contains testosterone decanoate with a half-life of approximately 15 days): begin SERM therapy 18 to 21 days after the last injection, governed by the longest ester in the blend.

For Nandrolone Decanoate (half-life approximately 15 days): begin SERM therapy 21 to 28 days after the last injection. Additionally, the 19-nor metabolites provide persistent low-level HPTA suppression for months, which is why some users run HCG during the extended clearance window.

For Trenbolone Acetate (half-life approximately 1 day): begin SERM therapy 4 to 5 days after the last injection. For Trenbolone Enanthate (half-life approximately 5 to 7 days): begin SERM therapy 14 to 21 days after the last injection. Like Nandrolone, Trenbolone is a 19-nor compound with persistent metabolites.

What does a standard PCT protocol look like?

For a straightforward testosterone-only cycle of 10 to 14 weeks, the standard PCT protocol is:

Tamoxifen 20mg daily for 4 to 6 weeks, beginning 14 days after the last injection of Testosterone Enanthate or Cypionate. Some protocols start at 40mg daily for the first week and taper to 20mg for the remaining weeks, though there is no controlled clinical data demonstrating that the taper produces superior testosterone recovery compared to a flat 20mg dose.

If Clomiphene is used instead (or in addition to Tamoxifen): Clomiphene 50mg daily for 4 weeks, or 50mg daily for 2 weeks followed by 25mg daily for 2 weeks. Clomiphene at 50mg daily is the dose with the most clinical data supporting gonadotropin stimulation.

For cycles involving 19-nor compounds (Nandrolone, Trenbolone), the PCT phase may need to be extended to 6 to 8 weeks, and on-cycle HCG is strongly recommended to maintain testicular function through the extended suppression period.

What happens if you skip PCT entirely?

Without PCT, testosterone recovery occurs passively, driven only by the gradual reawakening of the HPTA as exogenous androgen levels fall. The 2026 Andrology review analysed biochemical recovery in 641 men who had ceased AAS use within the preceding 36 months: only 48.2% had achieved hormonal recovery (normalisation of total testosterone, LH and FSH), and among those who had used PCT, 79.5% achieved biochemical recovery versus significantly fewer among non-users. Even with recovery, 29.5% of those who achieved biochemical normalisation still reported hypogonadal symptoms, suggesting that hormonal numbers and clinical wellbeing do not always align perfectly.

During the months of suppressed testosterone that follow an unassisted recovery, you experience: loss of libido and erectile function, loss of motivation and drive, depressed mood (which can be clinically significant, not merely “feeling down”), increased fat storage (particularly visceral and abdominal fat), rapid loss of muscle mass and strength (the catabolic environment without testosterone accelerates muscle protein breakdown), fatigue, poor sleep quality, and cognitive fog. Many users who skip PCT describe the post-cycle period as the worst they have ever felt, and the experience of losing months of hard-earned progress while feeling physically and psychologically terrible is a significant contributor to the cycle of repeated use: the temptation to start another cycle rather than endure the recovery period is powerful.

PCT does not eliminate these symptoms entirely, but it dramatically compresses the timeline: instead of months at near-castrate testosterone levels, a well-executed PCT protocol typically restores LH, FSH and testosterone to functional levels within 4 to 8 weeks, shortening the window of hypogonadal symptoms and reducing the total amount of muscle and strength lost during recovery.

How do you know when your PCT has worked?

The only reliable way to confirm that PCT has restored your HPTA is bloodwork. Subjective recovery (feeling better, libido returning, energy improving) is encouraging but not definitive: testosterone can be in the low-normal range while symptoms persist, or conversely, you can feel recovered while LH and FSH are still suppressed.

The confirmation protocol is straightforward. Draw blood 4 to 6 weeks after completing PCT and check: total testosterone, free testosterone, LH, FSH, oestradiol, and SHBG. Compare these values to your pre-cycle baseline (which is why baseline bloodwork before the cycle is essential). If total testosterone is within your pre-cycle range and LH and FSH are in the normal reference range, your HPTA has recovered. If LH and FSH are elevated above normal range with testosterone in the low-normal range, your pituitary is working hard but your Leydig cells have not yet fully recovered: this may normalise with time or may indicate partial Leydig cell damage from prolonged or repeated cycles.

A second confirmatory blood test at 10 to 12 weeks post-PCT is recommended, particularly after cycles involving 19-nor compounds, to confirm that the recovery is stable and not a transient SERM-induced spike that falls back after discontinuation.

For independently tested compounds with verified dosing accuracy, Hemi Pharma’s Janoshik lab results are published before sale. Product accuracy matters for PCT planning because your ester clearance calculations depend on the dose you actually took, not the dose you thought you took.

Frequently Asked Questions

Can you recover natural testosterone without PCT?

Yes, most men will eventually recover endogenous testosterone production without PCT, but the timeline is significantly longer (3 to 12 months versus 4 to 8 weeks with PCT), the depth of hypogonadal symptoms during recovery is more severe, and the amount of muscle and strength lost during the prolonged suppression is substantially greater. Data from 641 former AAS users showed that only 48.2% achieved hormonal recovery within 36 months without standardised PCT, compared to 79.5% biochemical recovery among those who used PCT protocols.

Is Nolvadex or Clomid better for PCT?

Both are effective SERMs that stimulate LH and FSH release. Tamoxifen (Nolvadex) is generally preferred because it is better tolerated: fewer emotional side effects, no visual disturbances, and the additional benefit of oestrogen receptor antagonism in breast tissue. Clomiphene (Clomid) contains a zuclomiphene isomer that accumulates and produces mild oestrogenic effects including mood disturbance. Some protocols combine both for a stronger gonadotropin response, though no controlled trial has compared dual-SERM to single-SERM PCT in steroid users.

Do you need PCT after a short or mild cycle?

Yes. Even a short cycle (6 to 8 weeks) of a mild compound like Anavar at low doses suppresses the HPTA. The degree of suppression may be less than a 16-week multi-compound cycle, but suppression still occurs and recovery still benefits from SERM therapy. The only scenario where PCT may be unnecessary is if the cycle was extremely short (under 4 weeks) and used a very mild compound at low doses, but even then, bloodwork should confirm recovery.

Can women use PCT after a steroid cycle?

Women do not use the same PCT protocol as men because the goal is different. Women do not need to restart testosterone production from the testes. The primary concerns for women after a steroid cycle are normalisation of menstrual function and monitoring for persistent virilisation. If menstrual irregularity persists beyond 2 to 3 months after stopping, medical evaluation is appropriate. SERMs can affect female reproductive hormones and should not be used without medical guidance.

How many times can you run PCT before it stops working?

There is no established limit on the number of PCT cycles, but each successive suppression-recovery cycle places cumulative stress on the HPTA. With each cycle, there is a small probability that recovery will be incomplete, and this probability increases with the number of cycles, the duration of each cycle, and the compounds used. Some long-term users find that after years of cycling, their baseline testosterone does not fully recover to pre-use levels, ultimately requiring ongoing testosterone replacement therapy.

References

Bandura AJ, et al. Clomiphene citrate in off-label post-cycle therapy: mechanisms, efficacy and diagnostic challenges in endocrine recovery following anabolic steroid use. Andrology. 2026. doi:10.1111/andr.70306

Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025. PMC12510335

de Ronde W, Smit DL. Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives. Front Endocrinol. 2025. PMC13588284

Shopping Basket
Scroll to Top